[1] 中国成人心肌炎临床诊断与治疗指南2024[J].中国分子心脏病学杂志,2024,24(4):6193-6207.
[2] Hang W, Chen C, Seubert JM, et al.Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes[J]. Signal Transduct Target Ther. 2020 ;5(1):287.
[3] 汪道文. 暴发性心肌炎诊断与治疗[M].北京:科学出版社, 2021: 19-27.
[4] Ammirati E, Cipriani M, Camici PG, et al.Response by Ammirati et al to Letter Regarding Article, "Survival and Left Ventricular Function Changes in Fulminant Versus Nonfulminant Acute Myocarditis"[J]. Circulation. 2018 ;137(13):1427-1428.
[5] 袁璟. 重症心肌炎的早期识别和救治[J].临床心血管病杂志,2021,37(2):97-100.
[6] Kociol RD, Cooper LT, Fang JC, et al American Heart Association Heart Failure and Transplantation Committee of the Council on Clinical Cardiology. Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association[J]. Circulation, 2020, 141(6):e69-e92.
[7] Tschöpe C, Ammirati E, Bozkurt B, et al.Myocarditis and inflammatory cardiomyopathy: current evidence and future directions.[J].Nat Rev Cardiol, 2021, 18(3):169-193.
[8] Gaizauskiene K, Leketaite K, Glaveckaite S, et al.Diagnostic Value of Cardiovascular Magnetic Resonance T1 and T2 Mapping in Acute Myocarditis: A Systematic Literature Review.[J].Medicina (Kaunas), 2024, 60(7):1162.
[9] 赵妍,党爱民,吕纳强,等. 暴发性心肌炎的临床特点与预测因素分析[J].中国分子心脏病学杂志,2021,21(5):4162-4167.
[10] 许桂芬,赵文香,黄宣明,等.暴发性心肌炎患者的心脏结构改变及随访[J].中华高血压杂志,2021,29(11):1129-1133.
[11] 钟夕艳. 成人重症病毒性心肌炎的相关影响因素分析[D]. 重庆医科大学, 2022.
[12] Jurcova I, Rocek J, Bracamonte-Baran W, et al.Complete recovery of fulminant cytotoxic CD8 T-cell-mediated myocarditis after ECMELLA unloading and immunosuppression[J]. ESC Heart Fail, 2020, 7(4):1976-1981.
[13] 中国成人暴发性心肌炎诊断和治疗指南[J]. 中华心血管病杂志, 2024, 52(1): 10-33. |
